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Directional coronary atherectomy was first developed by Simp-
son in 1984 to overcome the limitations of balloon angio-
plasty—abrupt vessel closure and restenosis. On the basis of
encouraging results from an uncontrolled registry of consecu-
tively treated patients, the Food and Drug Administration
(FDA) approved directional atherectomy in 1990 for general
use, and it gradually became accepted in the early 1990s by the
interventional cardiology community as an alternative to bal-
loon angioplasty.
In 1993 the reports of the first Coronary Angioplasty Versus
Excisional Atherectomy Trial (CAVEAT-I) and the Canadian
Coronary Atherectomy Trial (CCAT) were published together
in the New England Journal of Medicine (1,2). These random-
ized trials showed that directional coronary atherectomy
caused more myocardial infarctions than did balloon angio-
plasty, was more expensive, and failed to significantly lower the
rate of restenosis. Despite concerns about directional atherec-
tomy (3), Omoigui et al. (4) report in this issue of the Journal
that the 35 clinical sites participating in CAVEAT-I increased
their use of directional atherectomy during the year after
publication of the study from 10.7% of all interventional cases
in 1993 to 14.1% 1 year later. During the same time period, the
use of balloon angioplasty decreased from 83.8% to 68.5%.
What explains the increase in directional atherectomy proce-
dures performed by well informed investigators after publica-
tion of two negative trials?
Randomized trials and clinical practice. Several factors
that determine how randomized trials influence clinical prac-
tice, including the timing of the studies, direction of the
findings (positive or negative), analysis of the end points and
counterforces that emerge when unexpected results are ob-
tained (5). Some of these factors may help us understand the
CAVEAT paradox.
Timing. Meinert and Tonascia (5) write that the optimal
time to perform a randomized trial is before a treatment is
accepted or rejected in clinical practice. A trial carried out
after a treatment has already been accepted will have a smaller
effect than one that is carried out before a treatment is
established. By the time the randomized trials were reported in
1993, directional atherectomy had been in general, noninves-
tigational use for almost 3 years. Its growing acceptance was
based on the attractive concept that removing tissue with
atherectomy was superior to compressing it with balloons. This
concept was supported by several studies published at the time
suggesting that the strongest predictor of restenosis was the
size of lumen achieved at the time of the procedure, and that
directional atherectomy produced consistently larger lumens
than conventional balloon angioplasty (6,7).
Negative results. The randomized trials of directional
atherectomy not only failed to show that this treatment could
significantly reduce the rate of restenosis, but they raised
serious questions about the safety of the technique. These
negative results contradicted the prevailing notions about
directional atherectomy. However, it is a basic rule of clinical
trial research that studies with positive results are easier to
accept and translate into clinical practice than those with
negative findings (5).
Counterforces. A company whose product is threatened by
the results of a negative trial can be expected to provide
alternative explanations (5). Several investigators quickly
pointed out that directional atherectomy resulted in better
angiographic outcomes than did balloon angioplasty. In
CAVEAT-I, directional atherectomy produced a greater in-
crease in the diameter of the coronary artery than did balloon
angioplasty (1.05-mm vs. 0.86-mm increase) and produced a
favorable trend in the rate of restenosis (50% vs. 57%, p 5
0.06) (1). In CCAT, directional atherectomy enlarged the
lumen diameter more than did balloon angioplasty (1.45-mm
vs. 1.16-mm increase), but restenosis was identical in the two
treatment groups (46% vs. 43%) (2).
The impact of a randomized trial on clinical practice
depends on the number of persons in the medical community
who believe that a treatment is useful (5). Many investigators
believed that the benefits of tissue removal were intuitive, but
they were concerned that the extent of tissue removal in the
randomized trials was inadequate. The use of small atherec-
tomy devices in the majority of cases, retrieval of scant tissue
and lack of adjunctive balloon angioplasty for further lumen
enlargement were identified as factors responsible for the
“underwhelming” posttreatment diameter stenoses of 29% in
CAVEAT-I (1) and 26% in CCAT (2). These immediate
posttreatment results were thought to be responsible for the
inability of directional atherectomy to significantly lower the
rates of restenosis or to produce clinical benefits. Several
investigators were convinced that “optimal” atherectomy tech-
niques could consistently achieve ,10% diameter stenosis
without increasing the risk of myocardial infarction, a goal that
was later demonstrated in the Optimal Atherectomy Resten-
osis Study (8).
No alternative techniques available. Randomized trials
such as CAVEAT-I and CCAT establish only broad therapeu-
tic principles, not the precise details of a regimen (5). Although
it was recognized that directional atherectomy should not
substitute for balloon angioplasty for the broad range of low
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risk and moderately complex lesions studied in CAVEAT-I
and CCAT, it was believed that atherectomy could be used for
complex coronary lesions judged to be unsuitable for balloon
angioplasty. Directional atherectomy prevailed at a time when
no other advanced technique was available to overcome the
limitations of balloon angioplasty. The selective use of atherec-
tomy was justifiable for complex lesions in the era before
approval of coronary artery stenting, especially for situations in
which balloon angioplasty would have led to unsuccessful
outcomes or would have been complicated by emergency
bypass surgery.
Epilogue. Since 1994 several additional studies have eval-
uated the performance of directional atherectomy against
balloon angioplasty. In CAVEAT-II, 305 patients with lesions
in saphenous vein grafts were randomly assigned to treatment
with directional atherectomy or balloon angioplasty (9). Al-
though the initial lumen gain was greater with atherectomy
(1.45-mm vs. 1.12-mm increase), distal embolization was sig-
nificantly increased, and the rates of restenosis were similar at
6 months (46% for atherectomy vs. 51% for angioplasty). In
the Balloon Versus Optimal Atherectomy Trial (10), the
aggressive use of directional atherectomy resulted in larger
lumen diameters than balloon angioplasty (2.82 mm vs.
2.33 mm). However, a significant increase in the incidence of
postprocedural elevations of creatine kinase was seen (34.4%
vs. 14.4%), and similar rates of target vessel revascularization
at 1 year were reported (17.1% vs. 19.7%). Thus, the more
recent atherectomy studies replicated the findings of CAVEAT-I
and CCAT, as well as those of the recent randomized studies
of excimer laser and rotational atherectomy (11,12), demon-
strating that the ablative therapies could produce larger lu-
mens without achieving durable clinical benefit. In the overall
investigation of new devices for coronary intervention, the goal
of tissue removal to reduce restenosis has slowly lost favor and
in retrospect may have been another example of an attractive
theory becoming an accepted fact if it gets published often
enough.
What has happened to the use of directional atherectomy
since 1994? In their analysis, Omoigui et al. (4) evaluated the
use of directional atherectomy during two 1-week periods at
the 35 CAVEAT study sites. At the same time, financial
analysts have tracked the worldwide sales of various interven-
tional devices. The global sales of directional atherectomy
devices remained flat between 1993 and 1994 but fell off 33%
during 1995 and dropped another 58% in 1996 (13). It is too
simplistic to attribute these striking changes to the results of
randomized clinical trials or to what everybody claims to have
known about atherectomy all along. It is more realistic to
attribute the ultimate decrease in sales of directional atherec-
tomy devices to the landmark decision of the FDA to approve
coronary stenting (14). Since 1995, the use of coronary stenting
revolutionized the field of interventional cardiology because
this treatment successfully achieved the dual goals of produc-
ing better clinical and angiographic results than balloon angio-
plasty for many lesion types. If coronary stenting had not been
approved by the FDA or was unsuccessful in overcoming the
limitations of balloon angioplasty, the use of directional
atherectomy would have been refined and prevailed at mod-
erate levels in the progressive field of interventional cardiology
until better alternatives did become available.
I acknowledge and appreciate the critical review of this editorial by Marc A.
Pfeffer, MD, PhD and Robert L. Feldman, MD.
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Abbreviations and Acronyms
CAVEAT 5 Coronary Angioplasty Versus Excisional
Atherectomy Trial
CCAT 5 Canadian Coronary Atherectomy Trial
FDA 5 Food and Drug Administration
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